Risperidone-induced Myoclonus in a Young Patient with Schizophrenia

Risperidone is a widely used antipsychotic for treating schizophrenia and other psychotic disorders. While it is generally well-tolerated, it can lead to a range of adverse effects, including extrapyramidal symptoms, metabolic side effects, and neuroleptic malignant syndrome. This case report focuses on an uncommon adverse effect: myoclonus, observed in a young male with early-onset schizophrenia treated with risperidone. The case involved a young male patient diagnosed with early-onset schizophrenia who was treated with risperidone. The patient’s symptoms were monitored closely throughout the treatment process. Upon the emergence of myoclonic episodes, a dose reduction was implemented, followed by the discontinuation of risperidone. The patient exhibited significant improvement in symptoms after the dose reduction and subsequent discontinuation of risperidone. This case illustrates that risperidone-induced myoclonus can occur in younger patients, despite it being more commonly reported in elderly individuals with neurological comorbidities. This case underscores the necessity for vigilant monitoring of potential adverse effects in younger patients when initiating or adjusting antipsychotic medications. Clinicians should remain aware of the possibility of myoclonus and other uncommon side effects, even in populations typically considered at lower risk.